AmpliPhi Biosciences Signs Global R&D Agreement With US Army to Develop Bacteriophage Therapies to Treat Resistant Bacterial Infections
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
RICHMOND, Va. & SYDNEY & LONDON--(BUSINESS WIRE)--AmpliPhi BioSciences Corporation (OTC:APHB) (“AmpliPhi”), the leader in the discovery and development of bacteriophage-based therapies to treat drug resistant bacterial infections, announced today a Collaborative Research and Development Agreement (CRADA) with the United States Army Medical Research and Materiel Command (USAMRMC) and the Walter Reed Army Institute of Research (WRAIR).
Help employers find you! Check out all the jobs and post your resume.
RICHMOND, Va. & SYDNEY & LONDON--(BUSINESS WIRE)--AmpliPhi BioSciences Corporation (OTC:APHB) (“AmpliPhi”), the leader in the discovery and development of bacteriophage-based therapies to treat drug resistant bacterial infections, announced today a Collaborative Research and Development Agreement (CRADA) with the United States Army Medical Research and Materiel Command (USAMRMC) and the Walter Reed Army Institute of Research (WRAIR).
Help employers find you! Check out all the jobs and post your resume.